人工肝联合恩替卡韦治疗慢加亚急性肝衰竭的临床效果

Clinical effect of artificial liver combined with Entecavir in the treatment of chronic subacute liver failure

目的探讨人工肝联合恩替卡韦治疗慢加亚急性肝衰竭的临床效果。方法选取2017年10月~2019年2月赣州市第五人民医院收治的70例慢加亚急性早期肝衰竭患者作为研究对象,按照就诊单双号分为对照组(35例)和实验组(35例)。对照组采用常规内科及恩替卡韦治疗,实验组在常规内科治疗基础上,采用人工肝联合恩替卡韦治疗。比较两组患者的肝功能指标、救治效果、焦虑抑郁状态及日常生活活动能力。结果实验组前清蛋白(PA)、胆碱酯酶(CHE)高于对照组,血清总胆红素(TBil)低于对照组,差异有统计学意义(P<0.05)。实验组的救治总有效率高于对照组,差异有统计学意义(P<0.05)。实验组的焦虑自评量表(SAS)、抑郁自评量表(SDS)评分低于对照组,日常生活活动能力评定量表(Barthel)评分高于对照组,差异有统计学意义(P<0.05)。结论针对慢加亚急性肝衰竭(早期)疾病,临床使用人工肝联合恩替卡韦治疗效果确切,值得临床推广。

Objective To explore the clinical effect of artificial liver combined with Entecavir in the treatment of chronic subacute liver failure.Methods A total of 70 patients with chronic subacute early liver failure admitted to Ganzhou Fifth People′s Hospital from October 2017 to February 2019 were selected as the research subjects,they were divided into the control group(35 cases)and the experimental group(35 cases)according to the odd-even numbers.The control group was treated with conventional medical treatment and Entecavir,while the experimental group was treated with artificial liver combined with Entecavir on the basis of conventional medical treatment.The liver function index,treatment effect,anxiety and depression status and the ability of daily living were compared between the two groups.Results The prealbumin(PA)and cholinesterase(CHE)of the experimental group were higher than those of the control group,and the total serum bilirubin(TBil)was lower than that of the control group,the differences were statistically significant(P<0.05).The total effective rate of the experimental group was higher than that of the control group,the difference was statistically significant(P<0.05).The self-rating anxiety scale(SAS)and self-rating depression scale(SDS)scores in the experimental group were lower than those in the control group,and the activities of daily living scale(Barthel)score in the experimental group was higher than that in the control group,the differences were statistically significant(P<0.05).Conclusion For chronic and subacute liver failure(early stage)disease,the clinical use of artificial liver combined with entecavir is effective and worthy of clinical promotion.